All In Biotech

Drug Trial Radar · NCT02861534

A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001)

A Randomized Parallel-Group, Placebo-Controlled, Double-Blind, Event-Driven, Multi-Center Pivotal Phase III Clinical Outcome Trial of Efficacy and Safety of the Oral sGC Stimulator Vericiguat in Subjects With Heart Failure With Reduced Ejection Fraction (HFrEF) - VerICiguaT GlObal Study in Subjects With Heart Failure With Reduced EjectIon FrAction (VICTORIA)

Last checked: Nov 20, 2026Latest source record: Nov 15, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Title says "pivotal". Randomized with 5,050 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

5,050

Actual

Start

Sep 20, 2016

Primary completion

Jun 18, 2019

Study completion Sep 2, 2019

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
Collaborators
Bayer; Canadian VIGOUR Centre; Duke Clinical Research Institute
First posted
Aug 10, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, placebo-controlled, parallel-group, multi-center, double-blind, event driven study of vericiguat (MK-1242) in participants with heart failure with reduced ejection fraction (HFrEF). The primary hypothesis is vericiguat (MK-1242) is superior to placebo in increasing the time to first occurrence of the composite of cardiovascular (CV) death or heart failure (HF) hospitalization in participants with HFrEF.

Conditions

  • Heart Failure
  • Chronic Heart Failure With Reduced Ejection Fraction

Interventions

  • VericiguatDrug

    2.5, 5.0, or 10.0 mg orally once daily

  • Placebo for vericiguatDrug

    2.5, 5.0, or 10.0 mg orally once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to First Occurrence of Composite Endpoint of Cardiovascular (CV) Death or Heart Failure (HF) HospitalizationTime frame: Up to approximately 33 months (through primary analysis database cutoff date of 18-June-2019)

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.